百济神州“2款抗肿瘤1类新药”在华获批临床

药智网
28 Nov 2024

导读:均针对晚期实体瘤11月27日,据CDE官网显示, 百济神州 的注射用BG-T187、注射用BG-C477获得临床试验默示许可,均针对晚期实体瘤。据公开资料显示,BG-T187是一款EGFR/cMET三抗,BG-C477是一款CEA ADC药物。图片来源:CDE官网两款药物均为针对实体瘤的1类新药,且同属于治疗用 生物制品 。药智数据显示,近年来单抗和ADC药物市场规模持续增长,2024年有望...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10